<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02454959</url>
  </required_header>
  <id_info>
    <org_study_id>PT003013</org_study_id>
    <nct_id>NCT02454959</nct_id>
  </id_info>
  <brief_title>Crossover Study to Assess the Efficacy of PT003 With and Without a Valved Holding Chamber in Subjects With Moderate to Severe COPD</brief_title>
  <official_title>A Randomized, Phase III, Two-period, Open-label, Chronic-dosing (7 Days), Multicenter, Crossover Study to Assess the Efficacy, Safety and Pharmacokinetics of PT003 in Subjects With Moderate to Very Severe COPD With and Without a Valved Holding Chamber</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Randomized, Phase III, Two-period, Open-label, Chronic-dosing (7 Days),
      Multi-center, Crossover Study to Assess the Efficacy of PT003 in Subjects with Moderate to
      Severe COPD with and without a Valved Holding Chamber.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 1, 2015</start_date>
  <completion_date type="Actual">March 25, 2016</completion_date>
  <primary_completion_date type="Actual">March 25, 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Curve for Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) From 0 to 12 Hours (AUC0-12) on Day 8</measure>
    <time_frame>7 days of treatment</time_frame>
    <description>AUC0-12 was calculated using the trapezoidal rule based on FEV1 assessments at pre-dose, and 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 10 hours, 11.5 hours, and 12 hours post-dosing of study drug. Primary Outcome was calculated using the trapezoidal rule and was modeled conditionally on baseline FEV1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC0-12 on Day 8</measure>
    <time_frame>Day 8</time_frame>
    <description>Pharmacokinetic Parameter AUC0-12 of Glycopyrronium by Treatment on Day 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-12 on Day 8</measure>
    <time_frame>Day 8</time_frame>
    <description>Pharmacokinetic Parameter AUC0-12 of Formoterol by Treatment on Day 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax on Day 8</measure>
    <time_frame>Day 8</time_frame>
    <description>Pharmacokinetic Parameter Cmax of Glycopyrronium by Treatment on Day 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax on Day 8</measure>
    <time_frame>Day 8</time_frame>
    <description>Pharmacokinetic Parameter Cmax of Formoterol by Treatment on Day 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax on Day 8</measure>
    <time_frame>Day 8</time_frame>
    <description>Pharmacokinetic Parameter tmax of Glycopyrronium by Treatment on Day 8</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax on Day 8</measure>
    <time_frame>Day 8</time_frame>
    <description>Pharmacokinetic Parameter tmax of Formoterol by Treatment on Day 8</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>COPD</condition>
  <arm_group>
    <arm_group_label>GFF MDI (PT003) with Aerochamber</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) with Aerochamber Plus Valved Holding Chamber</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GFF MDI (PT003) without Aerochamber</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) without Aerochamber Plus Valved Holding Chamber</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GFF MDI (PT003) with Aerochamber</intervention_name>
    <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) with Aerochamber Plus Valved Holding Chamber</description>
    <arm_group_label>GFF MDI (PT003) with Aerochamber</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>GFF MDI (PT003) without Aerochamber</intervention_name>
    <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) without Aerochamber Plus Valved Holding Chamber</description>
    <arm_group_label>GFF MDI (PT003) without Aerochamber</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 40 years of age and no older than 80 at Screening

          -  Women of non-child bearing potential or negative serum pregnancy test at Screening,
             and agrees to acceptable contraceptive methods used consistently and correctly
             Screening until 14 days after final visit.

          -  Subjects with an established clinical history of COPD as defined by the American
             Thoracic Society (ATS)/European Respiratory Society (ERS)

          -  Current or former smokers with a history of at least 10 pack-years of cigarette
             smoking

          -  Pre- and post-bronchodilator FEV1/FVC ratio of &lt;0.70

          -  Post-bronchodilator FEV1 must be &lt;80% predicted normal value, calculated using NHANES
             III reference equations, and the measured FEV1 must also be ≥30% of predicted normal
             value.

        Exclusion Criteria:

          -  Significant diseases other than COPD, i.e., disease or condition which, in the opinion
             of the Investigator, may put the subject at risk because of participation in the study
             or may influence either the results of the study or the subject's ability to
             participate in the study.

          -  Women who are pregnant or lactating or women of childbearing potential who are not
             using an acceptable method of contraception.

          -  Subjects, who in the opinion of the Investigator, have a current diagnosis of asthma.

          -  Subjects who have been hospitalized due to poorly controlled COPD within 3 months
             prior to Screening or during the Screening Period.

          -  Subjects who have poorly controlled COPD, defined as acute worsening of COPD that
             requires treatment with oral corticosteroids or antibiotics within 6 weeks prior to
             Screening or during the Screening Period.

          -  Subjects who have clinically significant uncontrolled hypertension.

          -  Subjects who have cancer that has not been in complete remission for at least five
             years.

          -  Subjects with abnormal liver function tests defined as AST, ALT, or total bilirubin
             ≥1.5 times upper limit of normal at Screening and on repeat testing.

          -  Subjects with a diagnosis of angle closure glaucoma will be excluded, regardless of
             whether or not they have been treated. Subjects with a diagnosis of open angle
             glaucoma who have intraocular pressure controlled with medication(s) are eligible.

          -  Subjects with symptomatic prostatic hypertrophy that is clinically significant in the
             opinion of the Investigator. Subjects with a trans-urethral resection of prostate
             (TURP) or full resection of the prostate within 6 months prior to Screening are
             excluded from the study.

          -  Subjects with bladder neck obstruction or urinary retention that is clinically
             significant in the opinion of the Investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Colin Reisner</last_name>
    <role>Study Director</role>
    <affiliation>Pearl Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pearl Investigative Site</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 13, 2015</study_first_submitted>
  <study_first_submitted_qc>May 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 27, 2015</study_first_posted>
  <results_first_submitted>March 7, 2017</results_first_submitted>
  <results_first_submitted_qc>March 7, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 19, 2017</results_first_posted>
  <last_update_submitted>March 7, 2017</last_update_submitted>
  <last_update_submitted_qc>March 7, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This is a randomized, 2-period, open-label, chronic dosing (7 days), cross-over study conducted at 8 sites in the US.</recruitment_details>
      <pre_assignment_details>Subject received one week of study treatment for each of the treatment periods, separated by a washout period of 7-14 days between treatments. Intent-to-treat (ITT) Population is used for Participant Flow. By-sequence tabulations of the data were not pre-specified.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Overall Study</title>
          <description>All Randomized Patients</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GFF MDI (PT003) With Aerochamber</title>
              <participants_list>
                <participants group_id="P1" count="73"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>GFF MDI (PT003) Without Aerochamber</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="70"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol-Specified Criteria</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Modified-Intent-to-Treat (MITT) Population is a subset of the Intent-to-Treat (ITT) Population including subjects who received treatment and had post-treatment efficacy data for both treatment periods and is used for the baseline characteristics.</population>
      <group_list>
        <group group_id="B1">
          <title>MITT Population</title>
          <description>The Modified ITT (MITT) Population is a subset of the ITT Population including subjects who received treatment and had post dose efficacy data from both Treatment Periods. Data judged to be impacted by major protocol deviations were determined prior to unblinding and excluded. Statistical tabulations and analyses are by randomized treatment, but data obtained after subjects received an incorrect treatment have been excluded from the affected periods.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="68"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62.5" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Area Under the Curve for Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) From 0 to 12 Hours (AUC0-12) on Day 8</title>
        <description>AUC0-12 was calculated using the trapezoidal rule based on FEV1 assessments at pre-dose, and 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 10 hours, 11.5 hours, and 12 hours post-dosing of study drug. Primary Outcome was calculated using the trapezoidal rule and was modeled conditionally on baseline FEV1.</description>
        <time_frame>7 days of treatment</time_frame>
        <population>The primary analysis used the Modified-Intent-to-Treat (MITT) Population.</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI (PT003) With Aerochamber</title>
            <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003 (GFF MDI) 14.4/9.6 µg BID with Aerochamber Plus Valved Holding Chamber</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI (PT003) Without Aerochamber</title>
            <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003 (GFF MDI) 14.4/9.6 µg BID without Aerochamber Plus Valved Holding Chamber</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Curve for Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) From 0 to 12 Hours (AUC0-12) on Day 8</title>
          <description>AUC0-12 was calculated using the trapezoidal rule based on FEV1 assessments at pre-dose, and 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 10 hours, 11.5 hours, and 12 hours post-dosing of study drug. Primary Outcome was calculated using the trapezoidal rule and was modeled conditionally on baseline FEV1.</description>
          <population>The primary analysis used the Modified-Intent-to-Treat (MITT) Population.</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="67"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.538" spread="0.0228"/>
                    <measurement group_id="O2" value="1.516" spread="0.0227"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-12 on Day 8</title>
        <description>Pharmacokinetic Parameter AUC0-12 of Glycopyrronium by Treatment on Day 8</description>
        <time_frame>Day 8</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI (PT003) With Aerochamber</title>
            <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003 (GFF MDI) 14.4/9.6 µg BID with Aerochamber Plus Valved Holding Chamber</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI (PT003) Without Aerochamber</title>
            <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003 (GFF MDI) 14.4/9.6 µg BID without Aerochamber Plus Valved Holding Chamber</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-12 on Day 8</title>
          <description>Pharmacokinetic Parameter AUC0-12 of Glycopyrronium by Treatment on Day 8</description>
          <population>Pharmacokinetic Population</population>
          <units>h*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="56"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128.00" spread="85.63"/>
                    <measurement group_id="O2" value="111.39" spread="63.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>AUC0-12 on Day 8</title>
        <description>Pharmacokinetic Parameter AUC0-12 of Formoterol by Treatment on Day 8</description>
        <time_frame>Day 8</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI (PT003) With Aerochamber</title>
            <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003 (GFF MDI) 14.4/9.6 µg BID with Aerochamber Plus Valved Holding Chamber</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI (PT003) Without Aerochamber</title>
            <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003 (GFF MDI) 14.4/9.6 µg BID without Aerochamber Plus Valved Holding Chamber</description>
          </group>
        </group_list>
        <measure>
          <title>AUC0-12 on Day 8</title>
          <description>Pharmacokinetic Parameter AUC0-12 of Formoterol by Treatment on Day 8</description>
          <population>Pharmacokinetic Population</population>
          <units>h*pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.46" spread="43.29"/>
                    <measurement group_id="O2" value="78.49" spread="39.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax on Day 8</title>
        <description>Pharmacokinetic Parameter Cmax of Glycopyrronium by Treatment on Day 8</description>
        <time_frame>Day 8</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI (PT003) With Aerochamber</title>
            <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003 (GFF MDI) 14.4/9.6 µg BID with Aerochamber Plus Valved Holding Chamber</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI (PT003) Without Aerochamber</title>
            <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003 (GFF MDI) 14.4/9.6 µg BID without Aerochamber Plus Valved Holding Chamber</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax on Day 8</title>
          <description>Pharmacokinetic Parameter Cmax of Glycopyrronium by Treatment on Day 8</description>
          <population>Pharmacokinetic Population</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.03" spread="21.87"/>
                    <measurement group_id="O2" value="26.55" spread="15.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cmax on Day 8</title>
        <description>Pharmacokinetic Parameter Cmax of Formoterol by Treatment on Day 8</description>
        <time_frame>Day 8</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI (PT003) With Aerochamber</title>
            <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003 (GFF MDI) 14.4/9.6 µg BID with Aerochamber Plus Valved Holding Chamber</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI (PT003) Without Aerochamber</title>
            <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003 (GFF MDI) 14.4/9.6 µg BID without Aerochamber Plus Valved Holding Chamber</description>
          </group>
        </group_list>
        <measure>
          <title>Cmax on Day 8</title>
          <description>Pharmacokinetic Parameter Cmax of Formoterol by Treatment on Day 8</description>
          <population>Pharmacokinetic Population</population>
          <units>pg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.53" spread="5.88"/>
                    <measurement group_id="O2" value="13.07" spread="7.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax on Day 8</title>
        <description>Pharmacokinetic Parameter tmax of Glycopyrronium by Treatment on Day 8</description>
        <time_frame>Day 8</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI (PT003) With Aerochamber</title>
            <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003 (GFF MDI) 14.4/9.6 µg BID with Aerochamber Plus Valved Holding Chamber</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI (PT003) Without Aerochamber</title>
            <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003 (GFF MDI) 14.4/9.6 µg BID without Aerochamber Plus Valved Holding Chamber</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax on Day 8</title>
          <description>Pharmacokinetic Parameter tmax of Glycopyrronium by Treatment on Day 8</description>
          <population>Pharmacokinetic Population</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" spread="21.87" lower_limit="0.03" upper_limit="10.02"/>
                    <measurement group_id="O2" value="0.12" spread="15.11" lower_limit="0.03" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tmax on Day 8</title>
        <description>Pharmacokinetic Parameter tmax of Formoterol by Treatment on Day 8</description>
        <time_frame>Day 8</time_frame>
        <population>Pharmacokinetic Population</population>
        <group_list>
          <group group_id="O1">
            <title>GFF MDI (PT003) With Aerochamber</title>
            <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003 (GFF MDI) 14.4/9.6 µg BID with Aerochamber Plus Valved Holding Chamber</description>
          </group>
          <group group_id="O2">
            <title>GFF MDI (PT003) Without Aerochamber</title>
            <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003 (GFF MDI) 14.4/9.6 µg BID without Aerochamber Plus Valved Holding Chamber</description>
          </group>
        </group_list>
        <measure>
          <title>Tmax on Day 8</title>
          <description>Pharmacokinetic Parameter tmax of Formoterol by Treatment on Day 8</description>
          <population>Pharmacokinetic Population</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
                <count group_id="O2" value="67"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" spread="21.87" lower_limit="0" upper_limit="10.02"/>
                    <measurement group_id="O2" value="0.37" spread="15.11" lower_limit="0.37" upper_limit="10.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events collected from the time the subject signed consent up to the follow-up phone call 7-14 days after last dose of study drug.</time_frame>
      <desc>Any Adverse Events reported as starting during a Washout Period were assigned to the last randomized treatment received including those occurring during a Washout Period or the Follow-up Period. Serious adverse events collected from the time the subject signed consent up to 14 days following the last dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>GFF MDI (PT003) With Aerochamber</title>
          <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003 (GFF MDI) 14.4/9.6 µg BID with Aerochamber Plus Valved Holding Chamber</description>
        </group>
        <group group_id="E2">
          <title>GFF MDI (PT003) Without Aerochamber</title>
          <description>Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003 (GFF MDI) 14.4/9.6 µg BID without Aerochamber Plus Valved Holding Chamber</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="74"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="78"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Vessel puncture site swelling</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="74"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="74"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="74"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent it's opinions, or the opinions of the publication committee, if these differ with the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Colin Reisner, MD, FCCP, FAAAAI</name_or_title>
      <organization>Pearl Therapeutics, Inc.</organization>
      <phone>650-305-2600</phone>
      <email>creisner@pearltherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

